Other Events ·
Eton reports ET-700 pilot shows lower GI side effects than GALZIN but weaker copper inhibition
ETONEton Pharmaceuticals, Inc.
Eton Pharmaceuticals announced preliminary results from a randomized, double-blind, placebo-controlled pilot study of ET-700, an investigational extended-release zinc acetate formulation for Wilson disease. The study found significantly improved gastrointestinal tolerability with ET-700 compared to GALZIN, with treatment-related adverse events occurring in 1 of 12 participants versus 8 of 12. However, hepatic copper uptake decreased by only 12% with ET-700, compared to a 46% decrease with GALZIN and an 11% increase with placebo. To address the modest efficacy, Eton plans to evaluate faster-release formulations in additional study arms during 2027 to seek improved copper absorption inhibition while preserving the favorable safety profile. The company operates as an innovative pharmaceutical firm focused on developing and commercializing treatments for rare diseases.